Natera Inc

NTRA

Company Profile

  • Business description

    Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

  • Contact

    13011 McCallen Pass
    Building A Suite 100
    AustinTX78753
    USA

    T: +1 650 980-9190

    E: [email protected]

    https://www.natera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    4,434

Stocks News & Analysis

stocks

Investors overly concerned about AI impact on ASX share

Shares screen as undervalued after prolonged decline.
stocks

After earnings, is Palantir stock a buy, a sell, or fairly valued?

With higher-than-expected revenue expectations and a raised fair value estimate, here’s what we think of Palantir stock.
stocks

Rio Tinto and Glencore go their separate ways

Our view after merger talks end.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,175.901.500.02%
CAC 408,323.2849.440.60%
DAX 4025,014.87293.411.19%
Dow JONES (US)50,135.8720.200.04%
FTSE 10010,386.2316.480.16%
HKSE27,027.16467.211.76%
NASDAQ23,238.67207.460.90%
Nikkei 22556,363.942,110.263.89%
NZX 50 Index13,486.0839.710.30%
S&P 5006,964.8232.520.47%
S&P/ASX 2008,913.602.000.02%
SSE Composite Index4,123.0957.511.41%

Market Movers